Abstract
Durvalumab has improved the results of treatment of locally advanced, inoperable non-small-cell lung cancer. In the Czech Republic, durvalumab is reimbursed from the health insurance for several months.
Durvalumab is indicated as monotherapy for the treatment of adult patients with locally advanced, inoperable NSCLC with PD-L1 expression >= 1% who showed no progression after platinum-based chemoradiotherapy. Our report describes the case of a 66-year-old man who has been treated with durvalumab since August 2020, at the beginning thanks to payment permission according to § 16